Edwards Lifesciences Corp. Price Target Increased to $78.00 by Analysts at Canaccord Genuity (EW)
Stock analysts at Canaccord Genuity increased their price objective on shares of Edwards Lifesciences Corp. (NYSE:EW) from $74.00 to $78.00 in a report issued on Tuesday, AnalystRatingsNetwork.com reports. Canaccord Genuity’s price objective would suggest a potential upside of 10.48% from the company’s current price.
In other Edwards Lifesciences Corp. news, CEO Michael Mussallem unloaded 29,500 shares of Edwards Lifesciences Corp. stock in a transaction dated Thursday, January 9th. The shares were sold at an average price of $67.04, for a total transaction of $1,977,680.00. Following the transaction, the chief executive officer now directly owns 263,850 shares of the company’s stock, valued at approximately $17,688,504. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of other firms have also recently commented on EW. Analysts at Barclays cut their price target on shares of Edwards Lifesciences Corp. from $68.00 to $64.00 in a research note to investors on Tuesday, December 10th. They now have an “equal weight” rating on the stock. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note to investors on Tuesday, December 10th. They now have a $72.00 price target on the stock, down previously from $75.00. Finally, analysts at Wells Fargo & Co. downgraded shares of Edwards Lifesciences Corp. from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $74.12.
Shares of Edwards Lifesciences Corp. (NYSE:EW) traded up 2.71% on Tuesday, hitting $70.60. 1,310,226 shares of the company’s stock traded hands. Edwards Lifesciences Corp. has a 1-year low of $60.62 and a 1-year high of $94.61. The stock’s 50-day moving average is $65.30 and its 200-day moving average is $68.83. The company has a market cap of $7.724 billion and a P/E ratio of 19.55.
Edwards Lifesciences Corp. (NYSE:EW) last released its earnings data on Monday, October 28th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. The company had revenue of $496.00 million for the quarter, compared to the consensus estimate of $490.96 million. During the same quarter in the prior year, the company posted $0.58 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp. will post $3.05 earnings per share for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.